Article

How Many Knee Arthroscopies Are Wasted Money?

(AAOS2015) Evidence from large insurance databases shows that knee replacement often quickly follows arthroscopy or injections. It would make (economic and clinical) sense to go straight to surgery, the researchers contend.

An impressive number-crunching activity using insurance claims has produced an interesting observation about end-stage knee osteoarthritis (OA). The researchers contend that many arthroscopy and injection procedures may be unnecessary, because patients often proceed  to total knee replacement (TKR) within a matter of months.

Jeremiah Cohen MD and his coauthors scoured medical records from Medicare and United Health Care to see what happened beforehand to patients who ultimately had TKRs between 2007 and 2011. The search yielded almost 83,000 cases.

A statistically significant proportion of procedure charges (about 70%) traced to the year before surgery in both databases. About 8% of the Medicare patients and more than 10% of the UHC patients had arthroscopy, roughly a third of them less than six months before they had the same knee replaced.

About two-thirds of the Medicare patients and just under half of the UHC patients had knee injections before surgery, of which well more than half (62% in the case of Medicare and 74% among) UHC patients took place within six months of knee replacement.

Forgoing other procedures and opting for earlier knee replacement among patients whose knees seem to be deteriorating seems to make both economic and clinical sense, the team asserts. They are preparing the study for publication.

 

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.